<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01418430</url>
  </required_header>
  <id_info>
    <org_study_id>CHOP-Z</org_study_id>
    <nct_id>NCT01418430</nct_id>
  </id_info>
  <brief_title>Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)</brief_title>
  <official_title>HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College Hospital NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of the combination of CHOP plus
      daclizumab in patients with ATLL previously untreated with anthracycline based chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <condition>HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)</condition>
  <arm_group>
    <arm_group_label>CHOP-daclizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP-daclizumab</intervention_name>
    <arm_group_label>CHOP-daclizumab</arm_group_label>
    <other_name>CHOP-Zenapax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed ATLL requiring treatment

               1. Frank acute leukaemia or lymphoma subtypes

               2. Chronic and smouldering cases should be considered if they are symptomatic and
                  require therapy, or there is evidence of disease progression

          2. No previous treatment with anthracycline based cytotoxic chemotherapy

             a. Patients may have received interferon and /or zidovudine and/or non-anthracycline
             based therapy

          3. Age 18-75 years

          4. Written informed consent

        Exclusion Criteria:

          1. HIV 1 or 2 positivity

          2. Pregnancy or breast-feeding

          3. Concomitant chemo-radiotherapy

          4. Prior hepatic or renal insufficiency with a bilirubin or transaminases greater than 5
             times the normal range or a creatinine greater than 150Î¼mol/l (not related to
             hypercalcaemia) following rehydration

          5. Other concomitant neoplasms not related to HTLV-I

          6. Cardiac or respiratory insufficiency with an ECOG score of greater than 3

          7. Any serious active uncontrolled infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2011</study_first_submitted>
  <study_first_submitted_qc>August 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>August 19, 2011</last_update_submitted>
  <last_update_submitted_qc>August 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Antonio Pagliuca</name_title>
    <organization>King's College Hospital NHS Foundation Trust</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daclizumab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

